 "Alembic Pharma gets USFDA nod for anti-viral drug Amantadine Hydrochloride")
Drug firm Alembic Pharmaceuticals on Friday said it has received approval from the US health regulator for Amantadine Hydrochloride tablets, used for treatment ofinfluenza A virus.
The approved product is therapeutically equivalent to the reference listed drug product Symmetrel tablets of Endo Pharmaceuticals, Inc.
In a regulatory filing, Alembic Pharmaceuticals said "it has received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Amantadine Hydrochloride tablets in the strength of 100 mg".
Amantadine Hydrochloride tablets are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.
Quoting IQVIA data, Alembic Pharma saidAmantadine Hydrochloride Tablets, 100 mg have an estimated market size of USD 13 million for twelve months ending June, 2020.
IQVIA is an American multi-national company serving the combined industries of health information technology and clinical research.
Alembic now has a total of 132 ANDA approvals (114 final approvals and 18 tentative approvals) from USFDA.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app